The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: A systematic review

Annals of Hematology

Volumn 87, Issue 12, 2008, Pages 961-973

  Shehata, Nadine ^a   Walker, Irwin ^b   Meyer, Ralph ^c   Haynes, Adam E ^d   Imrie, Kevin ^e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Darbepoetin; Erythropoiesis stimulating agents; Erythropoietin; ESAs; Hematological malignancies; Lymphoproliferative disorders; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DIARRHEA; DRUG DOSE TITRATION; DRUG FATALITY; DRUG FEVER; DYSPNEA; EMBASE; FATIGUE; GRANULOCYTOPENIA; HEALTH CARE ORGANIZATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; LUNG EMBOLISM; MEDLINE; MYALGIA; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; VOMITING; WORKSHOP;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; LYMPHOMA; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 55649094675     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0525-5     Document Type: Review

References (45)

1. Kyle R (1975) Multiple myeloma. Review of 869 cases. Mayo Clin Proc 50:29
2. Moullet I, Salles G, Ketterer N et al (1998) Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 9:1109-1115 doi: 10.1023/A:1008498705032
3. Gordon LI, Harrington D, Andersen J (1992) Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced non-Hodgkin's lymphoma. N Engl J Med 327:1342
4. Meyer RM, Browman GP, Samosh ML et al (1995) Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386-2393
5. Dammacco F, Silvestris F, Castoldi B (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28:127-134 doi: 10.1007/ s005990050032
6. Österborg A, Boogaerts MA, Cimino R et al (1996) Recombinant human erythropoietin in transfusion-dependant anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multi-center study. Blood 87:2675-2682
7. Dammacco F, Castoldi G, Roedjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172-179 doi: 10.1046/j.1365-2141.2001.02715.x
8. Kleinman S, Chan P, Robillard P (2003) Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 17:120-162
9. The blood system for the future. In: Krever H. Commission of Inquiry on the blood system, Final Report. Ottawa, Canada. Canadian Government Publishing; 1997: 1046-1074. vol 3.
10. Bohlius J, Langensiepen S, Schwarzer G, et al. (2006) Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev, issue 3
11. Rizzo JD, Lichtin AE, Woolf SH et al (2008) American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update on the use of epoetin and darbepoetin. Blood 111:25-41 doi: 10.1182/blood-2007-08-109488
12. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 82:7580-7584 doi: 10.1073/pnas.82.22.7580
13. Hedenus M, Adriansson M, Miguel JS et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122:394-403 doi: 10.1046/j.1365-2141.2003.04448.x
14. Hedenus M, Hansen S, Taylor K et al (2002) Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79-86 doi: 10.1046/ j.1365-2141.2002.03774.x
15. Österborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol 20:2486-2494 doi: 10.1200/JCO.2002.08.131
16. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rappaport B, Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
17. Garton JP, Gertz MA, Witzig TE et al (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective randomized, placebo-controlled, double blind trial. Arch Intern Med 155:2069-2079 doi: 10.1001/archinte.155.19.2069
18. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313-318 doi: 10.1007/BF01696618
19. Cazzola M, Mesinger D, Battister V et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 12:4446-4453
20. Pangalis GA, Poziopoulos C, Angelopoulou MK, Siakantaris MP, Panayiotidis P (1995) Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin. Br J Haematol 89:627-629 doi: 10.1111/ j.1365-2141.1995.tb08374.x
21. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG (2005) Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo controlled trials. J Clin Oncol 23:6941-6948 doi: 10.1200/JCO.2005.03.434
22. Österborg A, Brandberg Y, Hedenus M (2005) Impact of epoetin-b on survival of patients with lymphoproliferative malignancies: Long-term follow up of a large randomized study. Br J Haematol 12:206-209 doi: 10.1111/j.1365-2141.2005.05440.x
23. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386-393 doi: 10.1046/ j.1365-2141.2003.04439.x
24. Morishima Y, Ogura M, Yoneda S, Sakai H, Tobinai K, Nishiwaki Y et al (2006) Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind dose-finding study. Jpn J Clin Oncol 36:655-661 doi: 10.1093/jjco/hyl097
25. Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA (2006) Quality of life and health benefits of early treatment of mild anemia. Cancer 107:1907-1909 doi: 10.1002/cncr.22221
26. Smith RE, Aapro MS, Ludwig H, Pinter T, Smakal M, Ciuleanu TE et al (2008) Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, mulitcenter randomized, double-blind, placebo controlled study. J Clin Oncol 26:1040-1050 doi: 10.1200/JCO.2007.14.2885
27. Straus DJ, Turner RR, Testa MA, Hayes JF, Sarokhan BJ, the Procrit Hematological Malignancies Study Group (2002) Epoetin alfa treatment improves quality of life and increase hemoglobin levels during chemotherapy for lymphoma, chronic lymphocytic leukemia and multiple myeloma patients with mild-to moderate anemia. Blood 100(11) Abstract 828
28. Rose E, Rai K, Revicki D, Brown R, Reblando J (1994) Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 526a. Abstract 2091.
29. Rai K, Rose E, Revicki D, Brown R, Reblando J (1995) Clinical and health status assessments in anaemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa. Eur J Cancer 31A(Suppl 5):S50-1 A232 (abstract)
30. Rubio-Martinez A, Recasens V, Mayayo P, Montanes A, Rubio-Félix D, Giraldo P (2003) Anaemia associated to multiple myeloma: Response to epoetin alpha. Hematol J 4(Suppl 1):S202 A258 (abstract)
31. Delarue R, Mounier N, Haioun C, Coiffier R, Gisselbrecht C, Ghesquieres H, et al. (2006) Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or R- C HOP 21: Preliminary results of the LNH03-6B Randomized GELA Study. Blood 108. Abstract 2436
32. Khuri FR (2007) Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356:2445 doi: 10.1056/NEJMp078101
33. Food and Drug Administration Oncologic Drugs Advisory Committee May 4, 2004 Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/ 4037b2.htm. Accessed May 2008
34. Leyland-Jones B, BEST Investigators and Study Group (2003). Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4(8):459-460 doi: 10.1016/S1470-2045(03)01163-X
35. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032 doi: 10.1200/JCO.2006.07.1514
36. Henke M, Laszing R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patient with anaemia undergoing radiotherapy: Randomized, double-blind, placebo controlled trial. Lancet 362:1255-1260 doi: 10.1016/S0140-6736(03)14567-9
37. Communication about an Ongoing Safety Review: Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp) http://www.fda.gov/cder/drug/early_comm/ ESA.htm. Accessed April 2, 2008.
38. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924 doi: 10.1001/ jama.299.8.914
39. Hopwood P, Stephens RJ, Machin D (1994) Approaches to the analysis of quality of life data: Experiences gained from a medical research council lung cancer working party palliative chemotherapy trial. MRC Lung Cancer Working Party Qual Life Res 3:339-352 doi: 10.1007/BF00451726
40. Staquet M, Berzon R, Osoba D, Machin D (1996) Guidelines for reporting results of quality of life assessment in clinical trials. Qual Life Res 5:496-502 doi: 10.1007/BF00540022
41. Cella D, Kallich J, McDermott A, Xu X (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 15:979-986 doi: 10.1093/annonc/mdh235
42. Streiner DL (2002) The case of the missing data: Methods of dealing with dropouts and other research vagaries. Can J Psychol 47:68-75
43. National Institute for Health and Clinical Excellence Appraisal consultation document - erythropoietin for anaemia induced by cancer treatment. Online resource. Available at: http://www.nice.org.uk/ page.aspx?o=263492. Accessed: November, 2007.
44. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. 2006 update. Eur J Cancer 43:258-270 doi: 10.1016/j.ejca.2006.10.014
45. National Comprehensive Cancer Network Clinical practice guidelines in oncology. Cancer- and treatment-related anemia. Version 2.2005. Online resource. Available at: http://www.nccn.org/professionals/physician_gls/ PDF/anemia.pdf. Accessed: March 2, 2006